Trials / Completed
CompletedNCT04303897
Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
A Real-World Evidence Study to Evaluate the Safety and Effectiveness of XEN Glaucoma Treatment System (XEN) in Chinese Patients With Refractory Glaucoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 59 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma. Participants will be (prospective) or have already been (retrospective) implanted with XEN via specific urgent medical need.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | XEN Glaucoma Stent | Data are collected from patients who are implanted with XEN via the specific urgent medical needs for named patient use regulatory pathway in Hainan |
Timeline
- Start date
- 2019-12-19
- Primary completion
- 2022-03-03
- Completion
- 2022-03-03
- First posted
- 2020-03-11
- Last updated
- 2024-04-12
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04303897. Inclusion in this directory is not an endorsement.